AMSTERDAM, July 5, 2011 /PRNewswire/ -- Oncimmune ® LLC, maker of EarlyCDT™-Lung , a simple blood test that aids physicians in the risk assessment and early detection of lung cancer , today announces that an abstract (P4.013) "EarlyCDT-Lung  test: audit of 1,000 patients in clinical practice" supports the previously published validation studies on EarlyCDT-Lung  with sensitivity for non-small cell lung cancer (NSCLC) at least as high as in the validation studies, including early stage disease. Leading lung cancer expert, James Jett, M.D., National Jewish Health, presents these findings Thursday, July 7, 2011, from 10:00 a.m. - 12:30 p.m. at Exhibition Hall, Amsterdam Rai, The Netherlands. The complete abstract can be accessed and viewed on the IASLC World Conference on Lung Cancer web site at http://www.2011worldlungcancer.org/abstracts.html .
"The EarlyCDT-Lung  test is a new technology with the potential to shift our ability to diagnose lung cancer earlier than is currently achieved," said James Jett, M.D., Professor of Medicine, National Jewish Health. "Data auditing the use of the test in clinical practice are consistent with the case-controlled studies. These data indicate that the EarlyCDT-Lung  test can risk stratify normal versus malignant nodules. The current guidelines that pulmonologists use for risk stratification and guiding the monitoring of CT nodules (Fleischner guidelines) a